Clinical trial · Interventional
Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
NCT00251550CI-TRIAL-00000958completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Mesotherioma | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate
Secondary outcomes (8)
- measure
- Duration of response
- measure
- Progression free survival
- measure
- Median survival time
- measure
- 1 year survival rate
- measure
- Pulmonary function
- measure
- QOL
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Inapplicable for radical operation * Not received prior systemic chemotherapy * Performance status: 0-1 Exclusion Criteria: * Having a history of sensitivity to platinum agent, folic acid or vitamin B12
References
Publications (0)
Data not yet available
No reference posted for this study.